Nicotinamide Mononucleotide (NMN) for Aging

Verdict: No proven anti-aging effect in humans

Despite striking results in mice, NMN has not been shown to slow human aging: the strongest pooled human evidence shows it raises blood NAD+ but fails to improve the clinical outcomes that actually matter. There is no human evidence it extends lifespan or healthspan.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

This claim earns a Counter-Evidence grade because the highest-quality human evidence is negative. A 2025 meta-analysis of glucose and lipid metabolism (PMID 39116016, n=513) found NMN raised blood NAD+ but left most clinically relevant metabolic outcomes unchanged, and the authors explicitly warned that NMN's benefits may be exaggerated. A second 2025 meta-analysis of muscle aging (PMID 40275690) found no significant effect on muscle mass, grip strength, or gait speed in adults over 60.

The supportive trials only reach surrogate endpoints. Two small, short, industry-funded RCTs (PMID 36482258, n=80; PMID 38789831, n=60) showed NAD+ rising and modest gains in walking or sleep, but PMID 38789831's pre-specified primary endpoint was null. No trial measures a hard lifespan or mortality outcome, and the dramatic mouse-longevity data have not carried over to humans.

Regulators and major clinics reinforce this caution. The US FDA states NMN 'is excluded from the definition of a dietary supplement,' and the EU EFSA's verdict is a safety opinion only (300 mg/day deemed safe), not an efficacy endorsement. The Mayo Clinic says such anti-aging approaches are 'not ready for prime time,' and the NIH's National Institute on Aging notes there is 'little, if any, science' behind supplement promises to help you live longer.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.50
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
75%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.30
L5 Clinical bodiesAuthoritative stance
0.43
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.504
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (2 negative > 0 positive),下層 RCT 不能推翻
  4. apply_hec_override — HEC-1 高階證據 negative — 強制由 C 改為 D
  5. tier_strict_requirement_check — Tier 條件達標,未降階
  6. detect_disputes — 偵測到 0 個 hard + 2 個 soft dispute
  7. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Efficacy of oral NMN supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on RCTs
PMID: 39116016 2025 統合分析 n = 513
Finding: NMN raised blood NAD+ but most clinically relevant metabolic outcomes did not differ from control; authors note possible exaggeration of NMN benefits.
View on PubMed
The Effect of NMN and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis
PMID: 40275690 2025 統合分析
Finding: No significant NMN benefit: SMI MD -0.42 (p=0.14), HGS left MD 0.61 (p=0.42), gait speed MD -0.01 (p=0.79); evidence does not support NMN for preserving muscle in adults >60 yrs.
Effect size: SMI MD -0.42; gait speed MD -0.01
View on PubMed
Efficacy and safety of beta-NMN supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, dose-dependent trial
PMID: 36482258 2023 RCT (double-blind) n = 80
Finding: NAD+ rose dose-dependently in all NMN groups (p<=0.001); walking distance improved (p<0.01); biological age stable vs placebo increase (p<0.05).
⚠️ Industry-funded
View on PubMed
Ingestion of beta-NMN increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults: double-blind RCT
PMID: 38789831 2024 RCT (double-blind) n = 60
Finding: Primary stepping test showed no difference; NMN group had shorter 4-m walking time (p<0.05) and lower PSQI global/daytime-dysfunction scores (p=0.013, p=0.010).
⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Against
NMN is excluded from the definition of a dietary supplement source↗
L4b EU EFSA
Neutral
EFSA considers a daily intake of 300 mg of NMN to be safe for the general population, excluding pregnant and lactating women. source↗
L4d TW TFDA / 衛福部
Cautious
違反食品安全衛生管理法第28條規定 source↗
L5b Mayo Clinic
Cautious
none of these approaches are ready for prime time source↗
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Cautious
Some advertisements for dietary supplements promise that some of these products will make you feel better, keep you from getting sick, or even help you live longer. It's important to know that often, there is little, if any, science supporting these claims. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-aging-INT-nicotinamide-mononucleotide-001 繁體中文版 →